Public Market Listing
000100KOSPI
Live quotes, historical charts, and market capitalization for Yuhan Corporation are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
9Total Assets
1Approved
3Phase 3 / Filed
5Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
Anplag tabNo recent activity | Phase 3 | Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule | Atherosclerotic Cardiovascular Disease |
| Phase 3 | HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component)Small molecule | Atherosclerotic Cardiovascular Disease | |
Sarpogrelate(Anplag) | Phase 3 | Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule | Atherosclerotic Cardiovascular Disease |
| Phase 1/2 | EGFR x 4-1BB (CD137)Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | HER2 exon 20 insertions; EGFR exon 20 insertionsSmall molecule | Non-Small Cell Lung Cancer | |
Monorova(Gemigliflozin) | Preclinical / Unstaged | HMG-CoA reductaseSmall molecule | Atherosclerotic Cardiovascular Disease |
RosuampinNo recent activity | Preclinical / Unstaged | HMG-CoA reductase / Calcium channelSmall molecule | Atherosclerotic Cardiovascular Disease |
| Preclinical / Unstaged | HMG-CoA reductase / NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.